Research programme: anticancer therapeutics - Cerylid Biosciences
Alternative Names: CBL 142; CBL 317; CBL 318; CBL-316; CBL-605; CBL-635; CBL-689; CBL-690Latest Information Update: 07 Feb 2011
At a glance
- Originator Cerylid Biosciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Aug 2003 Preclinical trials in Cancer in Australia (unspecified route)